Design Therapeutics reports Phase I/II RESTORE-FA trial outcomes

Design Therapeutics has reported data from the ongoing Phase I/II RESTORE-FA clinical trial assessing DT-216P2 in FA patients. The trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and exploratory clinical outcomes of DT-216P2. DT-216P2 is evaluated for the treatment of Friedreich ataxia patients. Credit: evan_huang / Shutterstock.com. Design Therapeutics has reported data from the ongoing Phase I/II RESTORE-FA clinical trial assessing DT-216P2 in Friedreich ataxia (FA) patients. The results show clinical improvements and increased biomarker activity following four weeks of intravenous treatment. LOA and PTSR Model DT-216 in Friedreich Ataxia Reports LOA and PTSR Model DTDEC-01 in…

Source: Clinical Trials Arena